Relationship between A1C and glucose levels in the general Dutch population: the new Hoorn study

Esther van 't Riet, Marjan Alssema, Josina M Rijkelijkhuizen, Piet J Kostense, Giel Nijpels, Jacqueline M Dekker, Esther van 't Riet, Marjan Alssema, Josina M Rijkelijkhuizen, Piet J Kostense, Giel Nijpels, Jacqueline M Dekker

Abstract

Objective: To investigate the relationship among A1C, fasting plasma glucose (FPG), and 2-h postload plasma glucose in the Dutch general population and to evaluate the results of using A1C for screening and diagnosis of diabetes.

Research design and methods: In 2006-2007, 2,753 participants of the New Hoorn Study, aged 40-65 years, who were randomly selected from the population of Hoorn, the Netherlands, underwent an oral glucose tolerance test (OGTT). Glucose status (normal glucose metabolism [NGM], intermediate hyperglycemia, newly diagnosed diabetes, and known diabetes) was defined by the 2006 World Health Organization criteria. Spearman correlations were used to investigate the agreement between markers of hyperglycemia, and a receiver operating characteristic (ROC) curve was calculated to evaluate the use of A1C to identify newly diagnosed diabetes.

Results: In the total population, the correlations between fasting plasma glucose and A1C and between 2-h postload plasma glucose and A1C were 0.46 and 0.33, respectively. In patients with known diabetes, these correlations were 0.71 and 0.79. An A1C level of > or =5.8%, representing 12% of the population, had the highest combination of sensitivity (72%) and specificity (91%) for identifying newly diagnosed diabetes. This cutoff point would identify 72% of the patients with newly diagnosed diabetes and include 30% of the individuals with intermediate hyperglycemia.

Conclusions: In patients with known diabetes, correlations between glucose and A1C are strong; however, moderate correlations were found in the general population. In addition, based on the diagnostic properties of A1C defined by ROC curve analysis, the advantage of A1C compared with OGTT for the diagnosis of diabetes is limited.

Figures

Figure 1
Figure 1
Scatter plots of FPG and 2-h postload plasma glucose in relation to A1C in the total population. Diabetic patients are indicated by dotted reference lines at FPG levels of 7.0 mmol/l and 2-h postload plasma glucose levels of 11.1 mmol/l.
Figure 2
Figure 2
ROC curve for identification of participants with previously undiagnosed diabetes, using A1C for diagnosis and an OGTT as criterion. A1C cutoff points of 5.8, 6.0, 6.5, and 7.0% are indicated on the curve.

References

    1. World Health Organization. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia: Report of a WHO/IDF Consultation. Geneva, World Health Org., 2006
    1. Nathan DM, Singer DE, Hurxthal K, Goodson JD: The clinical information value of the glycosylated hemoglobin assay. N Engl J Med 1984; 310: 341– 346
    1. Consensus Committee. Consensus statement on the worldwide standardization of the hemoglobin A1C measurement: the American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, and the International Diabetes Federation. Diabetes Care 2007; 30: 2399– 2400
    1. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ: Translating the A1C assay into estimated average glucose values. Diabetes Care 2008; 31: 1473– 1478
    1. Saudek CD, Herman WH, Sacks DB, Bergenstal RM, Edelman D, Davidson MB: A new look at screening and diagnosing diabetes mellitus. J Clin Endocrinol Metab 2008; 93: 2447– 2453
    1. International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009; 32: 1327– 1334
    1. Rutten GEHM, De Grauw WJC, Nijpels G, Goudswaard AN, Uitewaal PJM, Van der Does FEE, Heine RJ, Van Ballegooie E, Verduijn MM, Bouma M: NHG-standard diabetes mellitus type 2. Huisarts Wet 2006; 49: 137– 152 [in Dutch]
    1. Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE: Defining the relationship between plasma glucose and HbA1c: analysis of glucose profiles and HbA1c in the Diabetes Control and Complications Trial. Diabetes Care 2002; 25: 275– 278
    1. Buell C, Kermah D, Davidson MB: Utility of A1C for diabetes screening in the 1999–2004 NHANES population. Diabetes Care 2007; 30: 2233– 2235
    1. Rohlfing CL, Little RR, Wiedmeyer HM, England JD, Madsen R, Harris MI, Flegal KM, Eberhardt MS, Goldstein DE: Use of GHb (HbA1c) in screening for undiagnosed diabetes in the U.S. population. Diabetes Care 2000; 23: 187– 191
    1. Davidson MB, Schriger DL, Peters AL, Lorber B: Relationship between fasting plasma glucose and glycosylated hemoglobin: potential for false-positive diagnoses of type 2 diabetes using new diagnostic criteria. JAMA 1999; 281: 1203– 1210
    1. Glümer C, Jørgensen T, Borch-Johnsen K: Targeted screening for undiagnosed diabetes reduces the number of diagnostic tests: Inter99(8). Diabet Med 2004; 21: 874– 880
    1. Perry RC, Shankar RR, Fineberg N, McGill J, Baron AD: the Early Diabetes Intervention Program (EDIP). HbA1c measurement improves the detection of type 2 diabetes in high-risk individuals with nondiagnostic levels of fasting plasma glucose: the Early Diabetes Intervention Program (EDIP). Diabetes Care 2001; 24: 465– 471
    1. Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N: Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med 2004; 141: 413– 420
    1. Barr EL, Boyko EJ, Zimmet PZ, Wolfe R, Tonkin AM, Shaw JE: Continuous relationships between non-diabetic hyperglycaemia and both cardiovascular disease and all-cause mortality: the Australian Diabetes, Obesity, and Lifestyle (AusDiab) study. Diabetologia 2009; 52: 415– 424
    1. Modan M, Meytes D, Rozeman P, Yosef SB, Sehayek E, Yosef NB, Lusky A, Halkin H: Significance of high HbA1 levels in normal glucose tolerance. Diabetes Care 1988; 11: 422– 428
    1. Cohen RM, Smith EP: Frequency of HbA1c discordance in estimating blood glucose control. Curr Opin Clin Nutr Metab Care 2008; 11: 512– 517
    1. Cohen RM, Snieder H, Lindsell CJ, Beyan H, Hawa MI, Blinko S, Edwards R, Spector TD, Leslie RD: Evidence for independent heritability of the glycation gap (glycosylation gap) fraction of HbA1c in nondiabetic twins. Diabetes Care 2006; 29: 1739– 1743
    1. Pani LN, Korenda L, Meigs JB, Driver C, Chamany S, Fox CS, Sullivan L, D'Agostino RB, Nathan DM: Effect of aging on A1C levels in persons without diabetes: evidence from the Framingham Offspring Study and the National Health and Nutrition Examination Survey 2001–2004. Diabetes Care 2008; 31: 1991– 1996
    1. Khera PK, Joiner CH, Carruthers A, Lindsell CJ, Smith EP, Franco RS, Holmes YR, Cohen RM: Evidence for interindividual heterogeneity in the glucose gradient across the human red blood cell membrane and its relationship to hemoglobin glycation. Diabetes 2008; 57: 2445– 2452
    1. Cohen RM, Franco RS, Khera PK, Smith EP, Lindsell CJ, Ciraolo PJ, Palascak MB, Joiner CH: Red cell lifespan heterogeneity in hematologically normal people is sufficient to alter HbA1c. Blood 2008; 112: 4284– 4291
    1. Herman WH, Ma Y, Uwaifo G, Haffner S, Kahn SE, Horton ES, Lachin JM, Montez MG, Brenneman T, Barrett-Connor E: the Diabetes Prevention Program Research Group. Differences in A1C by race and ethnicity among patients with impaired glucose tolerance in the Diabetes Prevention Program. Diabetes Care 2007; 30: 2453– 2457
    1. Kilpatrick ES, Rigby AS, Atkin SL: Variability in the relationship between mean plasma glucose and HbA1c: implications for the assessment of glycemic control. Clin Chem 2007; 53: 897– 901
    1. Selvin E, Crainiceanu CM, Brancati FL, Coresh J: Short-term variability in measures of glycemia and implications for the classification of diabetes. Arch Intern Med 2007; 167: 1545– 1551
    1. de Vegt F, Dekker JM, Stehouwer CD, Nijpels G, Bouter LM, Heine RJ: Similar 9-year mortality risks and reproducibility for the World Health Organization and American Diabetes Association glucose tolerance categories: the Hoorn Study. Diabetes Care 2000; 23: 40– 44

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa